494 related articles for article (PubMed ID: 34638863)
21. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
[TBL] [Abstract][Full Text] [Related]
24. Adenoviral vectors for prodrug activation-based gene therapy for cancer.
Doloff JC; Waxman DJ
Anticancer Agents Med Chem; 2014 Jan; 14(1):115-26. PubMed ID: 23869779
[TBL] [Abstract][Full Text] [Related]
25. Modelling heterogeneity in viral-tumour dynamics: The effects of gene-attenuation on viral characteristics.
Jenner A; Yun CO; Yoon A; Kim PS; Coster ACF
J Theor Biol; 2018 Oct; 454():41-52. PubMed ID: 29857083
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
Wang X; Zhong L; Zhao Y
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
[TBL] [Abstract][Full Text] [Related]
27. Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy.
Hagedorn C; Kreppel F
Hum Gene Ther; 2017 Oct; 28(10):820-832. PubMed ID: 28854810
[TBL] [Abstract][Full Text] [Related]
28. Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment.
Osipov ID; Vasikhovskaia VA; Zabelina DS; Kutseikin SS; Grazhdantseva AA; Kochneva GV; Davydova J; Netesov SV; Romanenko MV
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680222
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
30. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
31. Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy.
Li S; Ou M; Wang G; Tang L
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8325-35. PubMed ID: 27557721
[TBL] [Abstract][Full Text] [Related]
32. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
[TBL] [Abstract][Full Text] [Related]
36. Ixovex-1, a novel oncolytic E1B-mutated adenovirus.
Anwar M; Arendt ML; Ramachandran M; Carlsson A; Essand M; Akusjärvi G; Alusi G; Öberg D
Cancer Gene Ther; 2022 Nov; 29(11):1628-1635. PubMed ID: 35596069
[TBL] [Abstract][Full Text] [Related]
37. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
38. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
39. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins.
Niemann J; Kühnel F
Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.
Watanabe M; Nishikawaji Y; Kawakami H; Kosai KI
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
